Transposon Therapeutics

Transposon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformational therapies for neurodegenerative and aging-related diseases driven by LINE-1 retrotransposon activity. Its lead asset, TPN-101 (censavudine), is a potent oral inhibitor of LINE-1 reverse transcriptase in late-stage development for progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS) / frontotemporal dementia (FTD), and Alzheimer's disease. The pipeline also includes follow-on novel nucleoside reverse transcriptase inhibitors (NRTIs) and Protein Kinase R inhibitors (PKRi) targeting pathways activated by LINE-1 and implicated in cognitive impairment. Surfaced as a portfolio company of Canaan Partners and added to the API Evangelist network; enrichment found a corporate marketing website only and no public API, developer, or machine-readable surface.

Transposon Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Neurodegeneration, and Clinical Stage.

Transposon Therapeutics’ developer surface includes support, product news, and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub
10.0/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiotechnologyPharmaceuticalsNeurodegenerationClinical StageDrug DevelopmentLife SciencesNeuroscience

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 10.0/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.8 / 17
Access Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/transposon-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Transposon Therapeutics Domain Security

TLSv1.2 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 2

The organization behind the API

Website
Website
 News
News

Source (apis.yml)

apis.yml Raw ↑ 
aid: transposon-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/transposon-therapeutics.png
name: Transposon Therapeutics
description: Transposon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformational therapies
  for neurodegenerative and aging-related diseases driven by LINE-1 retrotransposon activity. Its lead asset, TPN-101 (censavudine),
  is a potent oral inhibitor of LINE-1 reverse transcriptase in late-stage development for progressive supranuclear palsy
  (PSP), amyotrophic lateral sclerosis (ALS) / frontotemporal dementia (FTD), and Alzheimer's disease. The pipeline also includes
  follow-on novel nucleoside reverse transcriptase inhibitors (NRTIs) and Protein Kinase R inhibitors (PKRi) targeting pathways
  activated by LINE-1 and implicated in cognitive impairment. Surfaced as a portfolio company of Canaan Partners and added
  to the API Evangelist network; enrichment found a corporate marketing website only and no public API, developer, or machine-readable
  surface.
url: https://raw.githubusercontent.com/api-evangelist/transposon-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Neurodegeneration
- Clinical Stage
- Drug Development
- Life Sciences
- Neuroscience
apis: []
common:
- type: DomainSecurity
  url: security/transposon-therapeutics-domain-security.yml
- type: Website
  url: https://transposonrx.com
- type: PrivacyPolicy
  url: https://transposonrx.com/privacy.html
- type: TermsOfService
  url: https://transposonrx.com/termsofuse.html
- type: Support
  url: https://transposonrx.com/connect.html
- type: News
  url: https://transposonrx.com/news.html
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1